-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $9

Benzinga·08/06/2026 14:13:42
Listen to the news
Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $8 to $9.